OMB Moves The Wolf Amendment Government-Wide: §200.220's Covered-Foreign-Countries Ban And §200.202(e)'s Foreign Entity R&D Approval Requirement Restructure University International Research

For fifteen years, the line in federal research policy known as the Wolf Amendment has restricted NASA from using appropriated funds for bilateral cooperation with the People's Republic of China without explicit FBI certification. The provision, named for former Representative Frank Wolf and added to NASA appropriations bills annually since 2011, has been the singular example in U.S. federal grant practice of a hard country-specific collaboration ban. Every research administrator who has ever tried to add a Chinese national co-investigator to a NASA-funded experiment knows how the Wolf Amendment functions in practice: it is, mostly, a prohibition.

On May 29, 2026, the Office of Management and Budget proposed to take the Wolf Amendment posture and apply it to every federal grant-making agency at once. Two new sections in the proposed rewrite of 2 CFR Part 200 do most of the work. Proposed §200.220 prohibits the use of federal financial assistance "for collaboration with, or activities in, a covered foreign country, or with any entity owned or controlled by a covered foreign country." Proposed §200.202(e) layers on a separate requirement that no federal R&D award may flow to a foreign entity without "the written approval of one or more senior political appointees of the awarding agency." The defined covered foreign countries list — the People's Republic of China, the Russian Federation, the Islamic Republic of Iran, the Democratic People's Republic of Korea, Cuba, and the Bolivarian Republic of Venezuela — mirrors the list used in Commerce Department export-control rules and in the CHIPS and Science Act's research security provisions.

This piece complements our comprehensive analysis of the May 29 rewrite. Where that piece treats the political pre-issuance review and termination-for-convenience changes that dominate the news coverage, this one drills into the international-collaboration provisions that will reshape university research operations in ways the political-review provisions do not.

What the proposed text changes

The change from current practice is structural in three ways.

Coverage expands from NASA to every grant-making agency. Under current law, the Wolf Amendment binds NASA. The China Initiative-era research security frameworks bind grantees in disclosure terms — Section 117 of the Higher Education Act, the new NSPM-33 standard research security disclosure forms, the CHIPS Act §10632 conflicts-of-commitment requirements. None of those frameworks bans funded collaboration outright across all agencies. The proposed §200.220, applying through 2 CFR Part 200 to every federal grant-making agency, does. An NIH-funded biomedical researcher with a long-running collaboration at Peking University, a DOE-funded materials scientist with a co-investigator at the Russian Academy of Sciences, an NEH-funded historian with a research partner at the University of Havana — all hit the new wall.

The trigger is country, not behavior. Existing research security policy turns on the behavior of the foreign partner: undisclosed funding, talent-program participation, conflict of commitment. The proposed §200.220 turns on the country itself. A Chinese university whose researchers have no military affiliation, no Thousand Talents Program participation, no undisclosed funding — but whose institution sits in the People's Republic — is covered. A Russian colleague at a Western European university with no ties to Russian state institutions — but whose primary academic home is in Russia — is covered to the extent the collaboration runs through the home institution. The categorical nature of the ban means existing diligence procedures, which were designed to screen for specific behavioral red flags, do not produce the right answers.

Senior political appointee approval becomes a second filter for all foreign R&D. Even for countries not on the covered list, proposed §200.202(e) imposes a new gate: "No Federal R&D award may include a foreign entity as a recipient, subrecipient, or contractor without the written approval of one or more senior political appointees of the awarding agency." For a German Max Planck Institute collaborator on an NSF physics grant, for a Brazilian co-investigator on an NIH epidemiology study, for a UK university subaward on a DOE energy project — the foreign component now triggers an additional, individualized political-approval step that the existing research security framework does not require.

What "covered foreign country" actually catches

The defined list is short, but the operational scope is wide. Three categories of edge cases will absorb most of the early compliance attention.

Joint ventures and subsidiaries. A Hong Kong-incorporated subsidiary of a U.S. multinational is a foreign entity under §200.202(e). Whether it is "in or controlled by" the People's Republic of China under §200.220 turns on the post-2020 National Security Law's effect on Hong Kong's corporate-law status — a question on which U.S. agencies have given divergent answers. The Department of Commerce's Entity List has treated Hong Kong as substantially folded into mainland regulatory practice since 2020. The Department of State's travel-advisory regime treats Hong Kong as a separate jurisdiction. The proposed §200.220 does not resolve which posture controls.

Personnel rather than institutions. The text addresses "entities" but the research practice question is people. A U.S. university with no foreign-institutional collaboration but with a postdoctoral researcher on a J-1 visa from a covered country, paid from federal-grant funds, is doing work that involves a national of a covered foreign country but is not "collaborating with" a covered foreign entity. The proposed text appears to permit that arrangement, in tension with the visa-screening posture some federal agencies have taken under separate authority. The University of Florida's controversial 2023 policy preventing the hiring of Chinese nationals into certain research roles was based on Florida state law, not federal grant rules. The May 29 OMB rewrite does not appear to import that personnel-screening posture, but the ambiguity will draw comment.

Pass-through and consortium structures. A U.S. university subaward to a European partner that itself has a separate, non-federal subcontract to a Chinese institution is not directly covered by §200.220, because the Chinese institution is not receiving federal funds. The political pre-issuance review under §200.205, however, gives agency political appointees discretion to weight the consortium structure in the pre-issuance review and to refuse the award on that basis. The structural workaround that has historically allowed limited indirect Chinese collaboration through European intermediaries becomes operationally riskier in the May 29 framework, even where it remains technically permissible.

What universities should do in the next ninety days

The comment period closes July 13. The effective date is October 1. The operational window for university research administrators to position institutions is short.

Inventory the foreign-component portfolio. Pull every active federal award and identify the ones with a foreign subaward, a foreign consortium partner, a foreign subcontract, or a foreign-key-personnel arrangement. Sort by country, then by award end date. Awards ending before October 1, 2026 will close out under current rules. Awards extending into FY2027 and beyond will need to be reviewed against whatever the final §200.220 and §200.202(e) text says.

Identify covered-country exposure now. The list is short — PRC, Russia, Iran, DPRK, Cuba, Venezuela. Most universities will find that PRC exposure dominates the inventory. Quantify it: total federal-award dollars touching PRC entities, number of active subawards, number of PRC-national personnel in covered roles, dollar value of pending federal proposals with PRC components. The inventory becomes the basis for both the institution's comment letter and the institution's transition planning.

Front-load the proposal pipeline. Federal proposals submitted and awarded before October 1 will be governed by their award terms at the time of issuance, not by the new rule. Universities with PRC-collaborative proposals in the pipeline should accelerate submission where the science allows. Universities with such proposals on the planning horizon should consider whether the FY2026 submission window is the last realistic chance to submit a covered-country collaboration in the current regulatory environment.

Build the alternative-collaborator bench. For research areas where the long-standing PRC, Russian, or Iranian collaborator is the world expert, the institutional question is whether a comparable collaborator exists in a non-covered country and what the cost of switching is. For materials science with Chinese partners, the alternatives are often in Germany, Japan, South Korea, and Singapore. For Russian-language and Russian-history scholarship, the alternatives are scarcer and the substantive cost of switching is higher.

Engage on §200.202(e), not just §200.220. The covered-country ban will draw the headline opposition in the comment record. The senior-appointee approval requirement for all foreign R&D awards may, in operational terms, be the larger long-run constraint. A blanket approval requirement that runs every foreign entity — every Cambridge, every Toronto, every São Paulo — through a political-appointee desk creates a bottleneck that the agencies cannot staff and that the research community cannot route around. The comment record should address §200.202(e) on its operational merits: what threshold should apply (the proposed text has none), what time window should govern the appointee's decision (the proposed text is silent), what record should the appointee make of a denial (the proposed text does not require one). These are the operational questions on which OMB has historically been willing to clarify in final rules.

The strategic frame

The May 29 rewrite is, in many ways, a regulatory consolidation of the policy directions of the past five years: tighter research security disclosure under NSPM-33 and the CHIPS Act, narrower allowable cost categories, more explicit limits on what federal grant funds can subsidize. The international-collaboration provisions in §200.220 and §200.202(e) are the most consolidating step. They take what has been a patchwork of agency-specific restrictions, statutory provisions, and disclosure requirements and replace it with a single, government-wide framework anchored in country-specific prohibition plus political-appointee approval.

For the leadership of a research-intensive university, the question is not whether the final rule will be softer than the proposed text — it likely will be — but whether the directional posture survives. The directional posture says: foreign research collaboration, particularly with researchers from a defined set of countries, is no longer presumptively permitted with federal funds. The institutions that build operational capacity around that posture, and that comment substantively on the operational ambiguities in the proposed text, will be better positioned than the institutions that wait to see what the final October 1 text says.